==> picture [665 x 116] intentionally omitted <==

Annual General Meeting Jennifer Chow CEO and Managing Director November 15, 2022

DISCLAIMER

Certain statements contained in this presentation, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Chimeric (collectively, “Chimeric” or the “Company”) to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favorable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data,

information or studies to be completed or provided prior to their approval of our products.

Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This presentation may not contain all the details and information necessary for you to make a decision or evaluation. Neither this presentation nor any of its contents may be used for any other purpose without the prior written consent of the Company.

==> picture [696 x 52] intentionally omitted <==

COMMITTED TO BRINGING THE PROMISE OF CELL THERAPY TO LIFE

Traditional drug development focuses on delaying disease progression - not on a cure.

We believe that novel cellular therapies have the promise to cure cancer.

To bring that promise to life for more patients, the mission of Chimeric is to discover, develop and commercialize the most promising and innovative cell therapies.

==> picture [480 x 273] intentionally omitted <==

==> picture [565 x 288] intentionally omitted <==

“We can now conclude that CAR-T cells can CURE patients with leukemia”

Dr Carl June, MD

Richard W. Vague Professor in Immunotherapy Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine

CELL THERAPY ANTICIPATED TO BE THE FASTEST GROWING MARKET IN ONCOLOGY

==> picture [491 x 274] intentionally omitted <==

----- Start of picture text -----

2022 2027
MARKET MARKET
$265 BN $581BN
ONCOLOGY ONCOLOGY
$10.69 BN $42.37BN
CELL THERAPY CELL THERAPY
----- End of picture text -----

==> picture [238 x 284] intentionally omitted <==

----- Start of picture text -----

CAGR
8.2%
ONCOLOGY
31.7%
CELL THERAPY
----- End of picture text -----

Market Data Forecast, Global Cell Therapy Market Size, Share, Trends, Growth & COVID-19 Impact Analysis Report – Segmented By Technology, Type, Cell Source, Application, End-Users and Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa) – Industry Forecast (2022 to 2027)

CHIMERIC THERAPEUTICS CORPORATE SNAPSHOT

Multiple Assets with Positive Phase 1 Signals
Robust Clinical Development Plans with Broad Therapeutic Focus
Innovative and Diversified Portfolio of Next Generation Technologies
Industry Leading Team with Extensive Cell Therapy Experience

==> picture [493 x 365] intentionally omitted <==

----- Start of picture text -----

ASX: CHM
0.31
0.16
0.14
0.12
0.08
Nov. 21 Feb. 22 May 22 Aug. 22 Nov. 22
Share Price Nov. 13: Market Cap Nov. 13: ~$36M
52 Week Range: 0.08-0.31 Net Cash: AUS $8M (Sept 22)
Shares on Issue: 425 M Board / Mgmt. Ownership: 20%
Share Price AUS ($)
----- End of picture text -----

A YEAR OF MAJOR MILESTONES: November 2021- November 2022

==> picture [960 x 414] intentionally omitted <==

----- Start of picture text -----

CORE NK Option CDH17 CAR T CORE NK CDH17 VECTOR CORE NK
(CHM 0201) (CHM 2101) (CHM 0201) (CHM 2101) (CHM 0201)
From Case Western Sponsored Research Exercise of Licensed from University Sponsored Research
Reserve University Agreement with Penn Option of Pennsylvania Agreement
November February November
May June
2021 2022 2022 2022 2022
November February March
March June
2021 2022 2022
2022 2022
Positive DL1 Data Positive DL2 Data CDH17
Positive Phase 1 Data CORE NK
Phase 1A CLTX CAR T Phase 1A CLTX CAR T Nature Cancer
CORE NK Combination Trial
(CHM 1101) (CHM 1101) Preclinical
Clinical Trial Clinical Trial (CHM 0201) Clearance from FDA
Publication Clinical Trial
(CHM 0201+)
----- End of picture text -----

CHIMERIC CELL THERAPY PORTFOLIO

CUTTING EDGE INNOVATION WITH BROAD COMMERCIAL OPPORTUNITY

==> picture [937 x 401] intentionally omitted <==

----- Start of picture text -----

Novel Design
T Cells NK Cells
Autologous Allogeneic
(personal) (off-the-shelf)
CORE-NK Platform
Phase 1 Complete
CLTX CAR T CLTX CAR T
CDH17 CAR T
(ICT/ ICV) (IV) Next Gen. CLTX CDH17 Undisclosed
CORE-NK
GBM Solid CAR-NK CAR-NK CAR-NK
Platform
Solid Tumor
Phase 1 Tumor
----- End of picture text -----

DIFFERENTIATING CHIMERIC A DIVERSIFIED PORTFOLIO WITH A FOCUS ON CURATIVE INTENT

==> picture [90 x 60] intentionally omitted <==

Cancer Target Innovation T Cell Derived Therapies NK Cell Derived Therapies Personalized (Autologous) Therapies Off the Shelf (Allogeneic) Therapies